CLINICAL ROLE -
Study Shows Steady Rise of Multiple Sclerosis Prevalence in United States
The prevalence of multiple sclerosis in the United States has steadily grown over the past 5 years to nearly 1 million people.
Read More
Stem Cell Transplantation Shows Greater Benefits for Relapsing-Remitting MS
Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.
Ocrelizumab Superior or Comparable to Other Disease-Modifying MS Drugs
Ocrelizumab found more effective in reducing the risk of 12-week confirmed disability progression compared with 10 other treatments for relapsing multiple sclerosis.